What Is the TRIUMPH Programme for Retatrutide?
Short answer: TRIUMPH is the collective name for the phase 3 trials of Retatrutide that Eli Lilly began in 2023, following the phase 2 results published that year. The trials enrol adults with obesity or overweight, some with related conditions such as knee osteoarthritis or sleep apnoea, and run for well over a year each. Their results will decide whether the compound is submitted for approval.
Phase 3 trials are larger and longer than phase 2 and are designed to confirm the earlier findings in a broader population and to characterise safety. Until they report, the phase 2 paper remains the main published human dataset.
The programme is referenced on this site to place Retatrutide accurately: an investigational compound, not an approved medicine. Nothing here describes how it is used.
REVIVE LAB UAE supplies the pack for laboratory research use only. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.
Retatrutide Pack 20 mg — REVIVE LAB UAE
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
AED 1010 · Lot-specific COA on request · Cash on delivery or USDT (5% off) Order Retatrutide Pack UAE — Live Stock & Pricing
Research-Use Only Disclaimer: This page is published for laboratory and scientific research information purposes only. Nothing here constitutes medical advice, dosing guidance, or a therapeutic recommendation. Products supplied by REVIVE LAB UAE (revivelab.ae) — where applicable — are sold strictly as reference materials for research use, not for human or veterinary consumption. Buyers and readers are solely responsible for compliance with applicable UAE laws and institutional research ethics requirements.